Hologic Inc (HOLX)

Return on equity (ROE)

Sep 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019
Net income (ttm) US$ in thousands 789,500 466,500 515,100 456,000 484,100 753,000 990,200 1,302,000 1,512,100 1,551,800 1,715,500 1,869,700 2,034,400 1,902,700 1,378,100 1,110,500 493,500 451,000 83,600 -203,600
Total stockholders’ equity US$ in thousands 5,130,000 4,844,400 4,653,800 5,016,900 5,182,000 5,300,800 5,092,500 4,876,200 4,997,900 4,792,700 4,519,100 4,218,600 3,877,100 3,794,400 3,267,900 2,705,200 2,255,100 2,086,100 2,250,800 2,115,700
ROE 15.39% 9.63% 11.07% 9.09% 9.34% 14.21% 19.44% 26.70% 30.25% 32.38% 37.96% 44.32% 52.47% 50.14% 42.17% 41.05% 21.88% 21.62% 3.71% -9.62%

September 30, 2024 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $789,500K ÷ $5,130,000K
= 15.39%

Hologic Inc's return on equity (ROE) has fluctuated over the past few years. The ROE has generally been positive, indicating the company's ability to generate profit from shareholders' equity.

The ROE reached a peak of 52.47% in March 2021, reflecting strong profitability relative to equity. Subsequently, the ROE decreased but remained relatively high in the following quarters. However, the ROE declined significantly and even turned negative at -9.62% in September 2019.

Overall, Hologic Inc's ROE has shown variability, likely influenced by factors such as changes in profitability, equity structure, and financial management strategies. The company's ability to sustain healthy ROE levels over time will be crucial for demonstrating effective utilization of shareholder funds and creating long-term value.


Peer comparison

Sep 30, 2024

Company name
Symbol
ROE
Hologic Inc
HOLX
15.39%
GE HealthCare Technologies Inc.
GEHC
21.98%